Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | BLM | P54132 | 3/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052201 | 1.00 | MAPT (0.67) | MAPTKMT2AKDM4ELMNABLM | |
| SCHEMBL30528867 | 1.00 | MAPT (0.67) | MAPTKMT2AKDM4ELMNABLM | |
| Hydrochloric Acid SCHEMBL20513716 | 0.98 | MAPT (0.65) | MAPTKMT2AKDM4ELMNABLM | |
| Hydrochloric Acid SCHEMBL20513717 | 0.98 | MAPT (0.65) | MAPTKMT2AKDM4ELMNABLM | |
| SCHEMBL5326606 | 0.85 | KDM4E (0.52) | MAPTKMT2AKDM4ELMNABLM | |
| SCHEMBL11189552 | 0.84 | KDM4E (0.48) | MAPTKMT2AKDM4ELMNABLM | |
| Dl-Tryptophan SCHEMBL27962058 | 0.82 | KDM4E (0.97) | MAPTKMT2AKDM4ELMNABLM | |
| Tryptophan SCHEMBL27962055 | 0.82 | KDM4E (0.97) | MAPTKMT2AKDM4ELMNABLM | |
| SCHEMBL14282895 | 0.80 | ITGB2 (0.46) | MAPTKMT2AKDM4ELMNABLM | |
| Tryptophan SCHEMBL23141133 | 0.80 | KMT2A (1.00) | MAPTKMT2AKDM4ELMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | claimed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | claimed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20240279731-A1 | MULTI COLOR WHOLE-GENOME MAPPING AND SEQUENCING IN NANOCHANNEL FOR GENETIC ANALYSIS | DREXEL UNIVERSITY | 2024-08-22 | — | — | US | disclosed |
| EP-4355870-A1 | MULTICOLOR WHOLE-GENOME MAPPING AND SEQUENCING IN NANOCHANNEL FOR GENETIC ANALYSIS | Drexel University (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-117836429-A | Multicolor whole genome mapping and sequencing in nanochannels for genetic analysis | 德雷克塞尔大学 | 2024-04-05 | — | — | CN | disclosed |
| US-20240100184-A1 | METHODS OF PRECISE GENOME EDITING BY IN SITU CUT AND PASTE (ICAP) | UNIV ROWAN (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240035024-A1 | LINKED-READ SEQUENCING LIBRARY PREPARATION | UNIV DREXEL (US) | 2024-02-01 | — | — | US | disclosed |
| EP-2454272-A1 | NEUROTENSIN ANALOGUES FOR RADIOISOTOPE TARGETING TO NEUROTENSIN RECEPTOR-POSITIVE TUMORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006985-A1 | NEUROTENSIN ANALOGUES FOR RADIOISOTOPE TARGETING TO NEUROTENSIN RECEPTOR-POSITIVE TUMORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010085661-A1 | MODIFIED PEPTIDES AND THEIR USE | MUSC FOUNDATION FOR REASEARCH DEVELOPMENT (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20090105129-A1 | Combination therapy | XENOME LTD (AU) | 2009-04-23 | — | — | US | disclosed |
| US-20090105129-A1 | Combination therapy | XENOME LTD (AU) | 2009-04-23 | — | — | US | disclosed |
| US-20090062212-A1 | Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2 | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2009-03-05 | — | — | US | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MAPT 4377/4885KMT2A 4690/4885KDM4E 4724/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | MAPT 4465/4885KMT2A 4544/4885KDM4E 4718/4885 |
| US-20090105129-A1 | Combination therapy | OPRL1, SLC6A2, OPRK1 | MAPT 770/4885KMT2A 3222/4885KDM4E 4377/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | MAPT 3794/4885KMT2A 3586/4885KDM4E 2053/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | MAPT 4377/4885KMT2A 4690/4885KDM4E 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.